Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors. Read More
Subscribe to Updates
Get the latest tech, social media, politics, business, sports and many more news directly to your inbox.